New Haven, United States
Ascent Bio, with its slogan "Building the future of molecule intelligence," is an emerging player at the intersection of AI and healthcare. Founded in 2023, it originated as a spin-out from Smita Krishnaswamy's lab at Yale and is spearheaded by a team comprising Smita Krishnaswamy, PhD, Egbert Castro, PhD, and Xuefei Gao, MBA/MPH. This startup is headquartered in the United States and focuses on leveraging AI to design drugs, a niche promising high returns on investment.
Their initial offering, Faraday, is currently in beta launch and represents their ambition to create a sophisticated AI scientist. Backed by the Merck Digital Science Studio, though the terms of any associated financing remain undisclosed, it highlights a strong endorsement from a leading industry name.
Operating within the segments of AI, Healthcare, Information Technology, Pharmaceutical, and Machine Learning, Ascent Bio is well-poised to capture opportunities in these rapidly advancing fields. Its pioneering approach places it at the frontier of the biotech transformation journey.
BenchSci
